Dinuclear ruthenium(II) Schiff base complex: a first in vivo study in Swiss albino mice.

OBJECTIVES: Dinuclear ruthenium(II) Schiff base complex was selected for in vivo study among many other novel metal-based compounds, because of its previously proved in vitro anticancer and antibacterial properties. The aim was to investigate the potential toxicity of this compound in animal model through biochemical and histopathological assessment. METHODS: Adult Swiss albino mice of both sexes were divided into high-dose and low-dose group that received a single intraperitoneal dose of ruthenium complex (175 mg/kg and 25 mg/kg, respectively) and one control group (vehicle only). After a follow-up period of 14 days, animals were sacrificed to obtain blood samples and organs. RESULTS: The test compound was well tolerated in a low-dose group and did not cause any mortality. The histological findings and serum biochemistry suggested a reversible character of alterations found in vital organs of this group. However, in the high-dose group, adverse effects were more severe and indicated dose and gender-related toxicity. CONCLUSION: Mild side effects found in a low-dose group together with excellent in vitro properties, made dinuclear ruthenium(II) Schiff base complex a promising candidate for further investigation and development as anticancer and antimicrobial agent (Tab. 4, Fig. 6, Ref. 32).

[Personal experience in the treatment of single brain metastases and comparison with current neurosurgical approaches]. / Nasa iskustva u tretmanu pojedinacnih metastaza mozga i komparacija sa kurentnim neurohirurskim pristupom.

Single metastases of the brain treated from January 1989 do December 1992 at the Neurosurgical Clinic in Sarajevo have been presented. Our approach and selection of patients have also been showed. We have compared our work with current neurosurgical treatment of metastases of the brain. The lung have been the source of the single brain metastases in 67%. Anaplastic carcinoma have been the most common pathohistological diagnosis. Metastases have been found in the cerebrum in 80% cases. Percent of the males patients have been 67%. The most frequently, patients have been ages 40-59. The single brain metastases with good general condition of the patient have been operative treatment indication. Operative mortality have been 12%. All patients have been treated by radiotherapy after operating. Contrast-enhanced CT of the brain have used to make preoperative diagnosis.